Both options use GLP-1 therapy, but pills offer added convenience for those who prefer not to use injections
Each additional receptor target has produced incrementally better outcomes in clinical trials
For obesity treatment, dose escalation protocols starting at lower doses (e.g., 2 mg) and gradually increasing to maintenance doses (e.g., 4 mg, 8 mg, or 12 mg) have been studied Link below for more detailed information: Product Overview: Retatru/Cagrilintide is a dual-compound research peptide combining Retatru, a novel multi-agonist peptide with activity across GLP-1, GIP, and glucagon pathways, and Cagrilintide, an amylin analog
At the same time, they require strict adherence to dosing instructions and thoughtful counseling
The follicles will start producing new hair within three to four months
ADA 2026 Screen annually for anxiety, diabetes distress, sleep health, and fear of hypoglycemia